In 2020, the leading causes of pregnancy-related deaths in the United States were mental health conditions, cardiovascular conditions, and infection. These three leading underlying causes were responsible for over **** of all pregnancy-related deaths in 2020. Mental health conditions alone accounted for *********** of all pregnancy-related deaths in the U.S. showing how important it is to screen for postpartum depression. This statistic shows the percentage of pregnancy-related deaths in 38 U.S. states in 2020, by underlying cause.

Maternal mortality rates can vary significantly around the world. For example, in 2022, Estonia had a maternal mortality rate of zero per 100,000 live births, while Mexico reported a rate of 38 deaths per 100,000 live births. However, the regions with the highest number of maternal deaths are Sub-Saharan Africa and Southern Asia, with differences between countries and regions often reflecting inequalities in health care services and access. Most causes of maternal mortality are preventable and treatable with the most common causes including severe bleeding, infections, complications during delivery, high blood pressure during pregnancy, and unsafe abortion. Maternal mortality in the United States In 2022, there were a total of 817 maternal deaths in the United States. Women aged 25 to 39 years accounted for 578 of these deaths, however, rates of maternal mortality are much higher among women aged 40 years and older. In 2022, the rate of maternal mortality among women aged 40 years and older in the U.S. was 87 per 100,000 live births, compared to a rate of 21 among women aged 25 to 39 years. The rate of maternal mortality in the U.S. has risen in recent years among all age groups. Differences in maternal mortality in the U.S. by race/ethnicity Sadly, there are great disparities in maternal mortality in the United States among different races and ethnicities. In 2022, the rate of maternal mortality among non-Hispanic white women was about 19 per 100,000 live births, while non-Hispanic Black women died from maternal causes at a rate of almost 50 per 100,000 live births. Rates of maternal mortality have risen for white and Hispanic women in recent years, but Black women have by far seen the largest increase in maternal mortality. In 2022, around 253 Black women died from maternal causes in the United States.

In 2020, the leading causes of pregnancy-related deaths in the U.S. were different for different races and ethnicities. For example, mental health conditions were the leading cause of pregnancy-related deaths among ****************** women, while ****************** women mostly died from cardiovascular conditions, and******************* women from amniotic fluid embolism. This statistic shows the distribution of pregnancy-related deaths in 38 U.S. states in 2020, by underlying cause and ethnicity.

Estimates based on District hospital discharge data. Counts of and rates based on fewer than 10 births are suppressed for privacy reasons.

Source: Center for Policy Planning and Evaluation, DC Department of Health

Why This Matters

In recent decades, pregnancy-related deaths have risen in the United States. Although relatively rare and mostly preventable, the numbers are high relative to other high-income countries.

Leading underlying causes of pregnancy-related deaths include severe bleeding, cardiac and coronary conditions, and infections. Individual, social, and structural factors contribute to maternal death risk and trends, including maternal age, preexisting medical conditions, access to quality care, insurance, and longstanding racial and ethnic inequities.

Maternal mortality rates are disproportionately higher among birthing people who are Black, Indigenous, and people of color.

The District Response

Enhancements to District healthcare programs. Medicaid expansion provides greater access to prenatal care, extended postpartum Medicaid coverage for a full year, and reimbursement for doula services through all District programs. For a list of local and national resources on pregnancy and related topics, click here.

Paid family leave program providing 12 weeks to bond with a new child or care for a serious health condition, and 2 weeks specifically for prenatal care.

The District established the Maternal Mortality Review Committee, which investigates the causes of maternal deaths, and develops strategic frameworks to improve maternal health.

Sources:a National Institute for Population Research and Training, MEASURE Evaluation, International Centre for Diarrhoeal Disease Research (2012) Bangladesh Maternal Mortality and Health Care Survey 2010. Available: http://www.cpc.unc.edu/measure/publications/tr-12-87. Accessed October 15, 2012.b World Health Organization (ND) WHO Maternal Mortality Country Profiles. Available: www.who.int/gho/maternal_health/en/#M. Accessed 1 March 2015.c Lozano R, Wang H, Foreman KJ, Rajaratnam JK, Naghavi M, Marcus JR, et al. (2011) Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet 378(9797): 1139–65. 10.1016/S0140-6736(11)61337-8d UNFPA, UNICEF, WHO, World Bank (2012) Trends in maternal mortality: 1990–2010. Available: http://www.unfpa.org/public/home/publications/pid/10728. Accessed 7 October 2012.e Bangladesh Bureau of Statistics, Statistics Informatics Division, Ministry of Planning (December 2012) Population and Housing Census 2011, Socio-economic and Demographic Report, National Series–Volume 4. Available at: http://203.112.218.66/WebTestApplication/userfiles/Image/BBS/Socio_Economic.pdf. Accessed 15 February, 2015.f Mozambique National Institute of Statistics, U.S. Census Bureau, MEASURE Evaluation, U.S. Centers for Disease Control and Prevention (2012) Mortality in Mozambique: Results from a 2007–2008 Post-Census Mortality Survey. Available: http://www.cpc.unc.edu/measure/publications/tr-11-83. Accessed 6 October 2012.g Ministerio da Saude (MISAU), Instituto Nacional de Estatística (INE) e ICF International (ICFI). Moçambique Inquérito Demográfico e de Saúde 2011. Calverton, Maryland, USA: MISAU, INE e ICFI.h Mudenda SS, Kamocha S, Mswia R, Conkling M, Sikanyiti P, et al. (2011) Feasibility of using a World Health Organization-standard methodology for Sample Vital Registration with Verbal Autopsy (SAVVY) to report leading causes of death in Zambia: results of a pilot in four provinces, 2010. Popul Health Metr 9:40. 10.1186/1478-7954-9-40i Central Statistical Office (CSO), Ministry of Health (MOH), Tropical Diseases Research Centre (TDRC), University Teaching Hospital Virology Laboratory, University of Zambia, and ICF International Inc. 2014. Zambia Demographic and Health Survey 2013–14: Preliminary Report. Rockville, Maryland, USA. Available: http://dhsprogram.com/pubs/pdf/PR53/PR53.pdf. Accessed February 26, 2015.j Centers for Disease Control and Prevention (2014) Saving Mothers, Giving Life: Maternal Mortality.Phase 1 Monitoring and Evaluation Report. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services. Available at: http://www.savingmothersgivinglife.org/doc/Maternal%20Mortality%20(advance%20copy).pdf. Accessed 26 February 2015.k Central Statistical Office (CSO), Ministry of Health (MOH), Tropical Diseases Research Centre (TDRC), University of Zambia, and Macro International Inc. 2009. Zambia Demographic and Health Survey 2007. Calverton, Maryland, USA: CSO and Macro International Inc.Comparison of Maternal Mortality Estimates: Zambia, Bangladesh, Mozambique.

In 2021, it was estimated that the maternal mortality rate as a result of abortion in Argentina amounted to 0.25 deaths per 10,000 live births. Meanwhile, hypertension, edema, or proteinuria caused around 0.6 deaths per 10,000 live births in the South American country that year. As of that date, viral infections related to pregnancy were the leading cause of maternal death in Argentina, most of them related to COVID-19.

Five leading causes of confirmed maternal death by maternal age, United States, 2016–2017.

In 2023, non-Hispanic Black women had the highest rates of maternal mortality among select races/ethnicities in the United States, with 50.3 deaths per 100,000 live births. The total maternal mortality rate in the U.S. at that time was 18.6 per 100,000 live births, a decrease from a rate of almost 33 in 2021. This statistic presents the maternal mortality rates in the United States from 2018 to 2023, by race and ethnicity.

In 2022, there were around 5.61 infant deaths in the U.S. per 1,000 live births. The postneonatal mortality rate that year was 2.02 per 1,000 live births. Leading causes of infant mortality in the U.S. include congenital malformations, disorders related to short gestation and low birth weight, maternal complications, and sudden infant death syndrome.

BackgroundWhile the high prevalence of preterm births and its impact on infant mortality in the US have been widely acknowledged, recent data suggest that even full-term births in the US face substantially higher mortality risks compared to European countries with low infant mortality rates. In this paper, we use the most recent birth records in the US to more closely analyze the primary causes underlying mortality rates among full-term births.Methods and findingsLinked birth and death records for the period 2010–2012 were used to identify the state- and cause-specific burden of infant mortality among full-term infants (born at 37–42 weeks of gestation). Multivariable logistic models were used to assess the extent to which state-level differences in full-term infant mortality (FTIM) were attributable to observed differences in maternal and birth characteristics. Random effects models were used to assess the relative contribution of state-level variation to FTIM. Hypothetical mortality outcomes were computed under the assumption that all states could achieve the survival rates of the best-performing states. A total of 10,175,481 infants born full-term in the US between January 1, 2010, and December 31, 2012, were analyzed. FTIM rate (FTIMR) was 2.2 per 1,000 live births overall, and ranged between 1.29 (Connecticut, 95% CI 1.08, 1.53) and 3.77 (Mississippi, 95% CI 3.39, 4.19) at the state level. Zero states reached the rates reported in the 6 low-mortality European countries analyzed (FTIMR < 1.25), and 13 states had FTIMR > 2.75. Sudden unexpected death in infancy (SUDI) accounted for 43% of FTIM; congenital malformations and perinatal conditions accounted for 31% and 11.3% of FTIM, respectively. The largest mortality differentials between states with good and states with poor FTIMR were found for SUDI, with particularly large risk differentials for deaths due to sudden infant death syndrome (SIDS) (odds ratio [OR] 2.52, 95% CI 1.86, 3.42) and suffocation (OR 4.40, 95% CI 3.71, 5.21). Even though these mortality differences were partially explained by state-level differences in maternal education, race, and maternal health, substantial state-level variation in infant mortality remained in fully adjusted models (SIDS OR 1.45, suffocation OR 2.92). The extent to which these state differentials are due to differential antenatal care standards as well as differential access to health services could not be determined due to data limitations. Overall, our estimates suggest that infant mortality could be reduced by 4,003 deaths (95% CI 2,284, 5,587) annually if all states were to achieve the mortality levels of the best-performing state in each cause-of-death category. Key limitations of the analysis are that information on termination rates at the state level was not available, and that causes of deaths may have been coded differentially across states.ConclusionsMore than 7,000 full-term infants die in the US each year. The results presented in this paper suggest that a substantial share of these deaths may be preventable. Potential improvements seem particularly large for SUDI, where very low rates have been achieved in a few states while average mortality rates remain high in most other areas. Given the high mortality burden due to SIDS and suffocation, policy efforts to promote compliance with recommended sleeping arrangements could be an effective first step in this direction.

This statistic shows the percentage of pregnancy-related deaths in the U.S. that were preventable from 2008 to 2017, by two of the major causes. During this time period it was estimated that ** percent of pregnancy-related deaths caused by hemorrhage were preventable.

In 2021, a total of 13 people died due to complications following an abortion in Argentina. Meanwhile, 34 deaths were reported due to hypertension, edema or proteinuria during pregnancy, childbirth or puerperium. According to a survey carried out in the South American country in November 2020, more than a third of respondents strongly disagreed with the decriminalization of abortion.

The dataset contains counts, rates, and measures of association between select risk factors and administratively identified maternal sepsis among live births during the pregnancy, delivery, and postpartum windows between 2016 and 2018. Maternal sepsis is a leading cause of maternal mortality in the United States and is associated with increased rates of preterm labor, preterm delivery and fetal infection and maternal chronic pain and fertility problems. Live births were identified from administrative coding of SPARCS acute care hospital claims between January 1, 2016 and December 31, 2018. Sepsis events were identified from SPARCS claims linked to these live birth events through a maternal identifier and occurring during pregnancy, delivery or within 42 days postpartum. Counts, rates, and measures of association are calculated within each of these thee windows separately. Sepsis events are quantified for ‘Any Sepsis’ and ‘Severe Sepsis/Septic Shock’ (a subset of ‘Any Sepsis’). Risk factors are captured using administrative coding from all SPARCS claims data available for each live birth during pregnancy or delivery, or from a linked birth certificate, when available. Counts, rates, and measures of association are presented for each risk factor and maternal sepsis in the specified window for all eligible statewide live births between 2016 and 2018.

"Note: Counts of and rates based on fewer than 10 births are suppressed for privacy reasons.

Source: Center for Policy Planning and Evaluation, DC Department of Health

Why This Matters

Preterm birth is a leading cause of infant deaths in the United States. Babies born preterm are also at an increased risk of breathing problems, feeding difficulties, cerebral palsy, developmental delay, vision problems, and hearing problems.

Nationally, approximately one in ten babies are born preterm. Factors such as maternal age, pregnancy history, medical conditions, lifestyle, and access to health care contribute to preterm births.

Preterm birth rates are highest among infants born to Black and Native American mothers. These disparities are associated with racism-related stress and structural barriers to education, quality health care, affordable housing, and sustainable income that disproportionately affect communities of color.

The District Response

Enhancements to District healthcare programs. Medicaid expansion provides greater access to prenatal care, extended postpartum Medicaid coverage for a full year, and reimbursement for doula services through all District programs. For a list of local and national resources on pregnancy and related topics, click here.

Supports mother and infant health outcomes through DC Women, Infants and Children (WIC) and various perinatal health programs, partnering with community-based organizations, healthcare institutions, and District agencies.

Paid family leave program provides 12 weeks to bond with a new child or care for a serious health condition, and 2 weeks specifically for prenatal care.

Postpartum Hemorrhage (PPH) Devices Market Outlook

The global postpartum hemorrhage (PPH) devices market is anticipated to witness significant growth, with market size estimated at USD 710 million in 2023 and projected to reach approximately USD 1.42 billion by 2032, reflecting a robust CAGR of 7.9% during the forecast period. This growth is primarily driven by increasing awareness of maternal health, advancements in medical technology, and rising healthcare expenditure globally. The escalating demand for effective PPH management solutions has placed a spotlight on the importance of innovative devices that can reduce maternal mortality rates associated with childbirth complications.

One of the key growth factors driving the PPH devices market is the increasing prevalence of postpartum hemorrhage, which remains a leading cause of maternal mortality worldwide. Efforts by international healthcare organizations and governments to reduce maternal mortality rates have heightened the focus on improving healthcare infrastructure and access to life-saving medical devices. Additionally, educational campaigns aimed at both healthcare providers and expectant mothers about the risks and management of PPH have led to increased adoption of PPH devices. This increased awareness and the availability of advanced medical solutions are crucial in empowering healthcare providers to offer timely and effective interventions.

Technological advancements have also been a significant catalyst for the growth of the PPH devices market. Innovations in medical device engineering have led to the development of more effective and user-friendly PPH management devices, which are crucial in emergency obstetric care. For instance, advancements in uterine balloon tamponade technology have made these devices more efficient, easy to use, and accessible, contributing to increased adoption across healthcare settings. Moreover, ongoing research and development activities are expected to introduce novel PPH devices that can offer enhanced performance and better outcomes, further propelling market growth.

The increasing investments in healthcare infrastructure, particularly in emerging economies, are another pivotal factor scaling the PPH devices market. Countries in Asia Pacific and Latin America are witnessing significant improvements in their healthcare systems, driven by both governmental initiatives and private sector investments. This has resulted in greater access to advanced medical facilities and a broader availability of PPH management devices. Additionally, as the global population continues to grow, there is a corresponding increase in childbirth rates, further emphasizing the need for effective PPH management solutions.

Regionally, the postpartum hemorrhage devices market is expanding at a varied pace across different geographical areas. North America, with its well-established healthcare infrastructure and high level of healthcare awareness, holds a substantial share of the market. On the other hand, Asia Pacific is expected to witness the highest CAGR due to rapidly improving healthcare facilities and increasing government initiatives to enhance maternal healthcare services. Europe also represents a significant market, driven by the rising demand for advanced medical devices and a strong focus on reducing maternal mortality rates. Meanwhile, regions like Latin America and the Middle East & Africa are gradually catching up, powered by both improvements in healthcare access and rising awareness about maternal health challenges.

Product Type Analysis

The product type segment of the PPH devices market is diverse, encompassing uterine balloon tamponade, non-pneumatic anti-shock garments, surgical instruments, and other devices. Among these, uterine balloon tamponade devices hold a dominant position, attributed to their effectiveness in controlling excessive bleeding postpartum and their ease of use. These devices are increasingly preferred in both developed and developing countries due to their minimally invasive nature and high success rates in managing PPH. The constant evolution in design and materials used in these devices further enhances their adoption, offering improved patient outcomes and ease of deployment during emergencies.

Non-pneumatic anti-shock garments (NASGs) have emerged as a critical tool in the management of postpartum hemorrhage, particularly in low-resource settings. These garments are designed to stabilize women experiencing severe obstetric bleeding by providing temporary hemostatic control and improving blood circulation to vital organs. Their cost-effectiveness, coupl

AI Pre-Eclampsia Polygenic Risk Calculator Market Outlook

According to our latest research, the global AI Pre-Eclampsia Polygenic Risk Calculator market size reached USD 312 million in 2024, driven by the increasing adoption of advanced AI tools in maternal health. The market is expected to grow at a robust CAGR of 18.2% from 2025 to 2033, with a projected market value of USD 1,573 million by 2033. This impressive growth is primarily attributed to the rising prevalence of pre-eclampsia, growing awareness of personalized medicine, and significant investments in healthcare AI technologies. As per our latest research, the market continues to gain traction as healthcare systems globally focus on early detection and risk stratification to improve maternal and fetal outcomes.

The primary growth driver for the AI Pre-Eclampsia Polygenic Risk Calculator market is the escalating incidence of pre-eclampsia worldwide, which affects approximately 5-8% of all pregnancies and remains a leading cause of maternal and neonatal morbidity and mortality. Traditional risk assessment methods often fall short in accurately predicting pre-eclampsia, leading to late interventions and adverse outcomes. The integration of AI-driven polygenic risk calculators enables clinicians to analyze vast genomic datasets, identify high-risk individuals earlier, and tailor preventive strategies accordingly. These advanced tools leverage machine learning algorithms to process genetic, clinical, and environmental data, providing a much higher predictive accuracy than conventional models. With healthcare providers increasingly seeking solutions that offer proactive risk management, the demand for AI-based risk calculators is expected to surge rapidly over the forecast period.

Another significant factor fueling market expansion is the ongoing digital transformation in healthcare, characterized by the widespread adoption of electronic health records (EHRs), cloud computing, and interoperable data platforms. These technological advancements have created a fertile environment for the deployment of sophisticated AI solutions, including polygenic risk calculators for pre-eclampsia. The ability to seamlessly integrate these tools with existing clinical workflows enhances their utility and adoption rates among hospitals, clinics, and research institutes. Moreover, supportive government policies, increasing funding for AI research in healthcare, and growing collaborations between technology providers and medical institutions are accelerating the commercialization and implementation of these solutions globally. The trend towards personalized medicine, where interventions are tailored to individual genetic profiles, further amplifies the market’s growth trajectory.

Furthermore, the rising awareness among both patients and healthcare professionals regarding the benefits of early risk prediction and intervention is catalyzing the adoption of AI polygenic risk calculators. Educational initiatives, professional training programs, and patient advocacy efforts are contributing to a more informed healthcare ecosystem that values precision diagnostics and preventive care. Additionally, the COVID-19 pandemic has underscored the importance of leveraging digital health technologies for remote monitoring and risk assessment, further validating the role of AI-powered tools in modern obstetric care. As more clinical validation studies demonstrate the efficacy and reliability of these calculators, regulatory approvals and reimbursement pathways are expected to become more streamlined, removing barriers to widespread adoption and driving sustained market growth.

From a regional perspective, North America currently dominates the AI Pre-Eclampsia Polygenic Risk Calculator market, accounting for the largest share in 2024, followed closely by Europe and Asia Pacific. The high prevalence of pre-eclampsia, advanced healthcare infrastructure, and proactive adoption of AI technologies in the United States and Canada are major contributors to North America’s leadership. Europe is witnessing significant momentum due to its robust research ecosystem and supportive regulatory landscape. Meanwhile, Asia Pacific is emerging as a high-growth region, propelled by increasing healthcare investments, rising awareness, and government initiatives aimed at reducing maternal mortality rates. Latin America and the Middle East & Africa, while currently holding smaller market shares, are expected to register notable growth as healthcare modernization and AI adoption accelerate

Hospital-based recruitment of females seeking termination of pregnancy or post-abortion care at a Zambian government health facility. The research used an innovative mixed methods interview which combined quantitative and qualitative techniques in one interview. Each participant was interviewed by two research assistants (RAs). One RA led the interview, using a conventional interview schedule in the manner of a qualitative semi-structured interview, while the second RA listened and, where possible, completed the quantitative ‘data sheet’. When the first RA has completed the qualitative part of the interview, interviewer two took over and asked the participant any remaining questions not yet answered on the data sheet. This technique allowed us to capture both the individual fine-grained narratives, which are not easily captured in a questionnaire-type survey, especially on such a sensitive area, as well as survey data. Rather than conducting an in-depth qualitative interview and a survey, our method reduced the burden on the respondent, avoiding repetition of questions and reducing the time taken. The quantitative data was used to establish the distribution of out-of-pocket expenses, for women and their households, incurred using hospital-based safe abortion and PAC services. Qualitative data established the range of reasons why women sought abortion, and why they used or did not use safe abortion services, and explored the social costs and benefits of their trajectories, and the policy implications. Unsafe abortion is a significant, preventable, cause of maternal mortality and morbidity and is both a cause and a consequence of poverty. Unsafe abortion is the most easily prevented cause of maternal death. Post-abortion care (PAC) is a strategy to address the problem of the outcomes of unsafe abortion.This research aims to establish how investment in safe abortion services impacts on the socio-economic conditions of women and their households, and the implications for policy-making and service provision in Zambia. The microeconomic impact of out-of-pocket health expenditure for reproductive health and abortion care, have received little attention.The data available for sub-Saharan Africa are particularly scanty and poor quality. The approach is multi-disciplinary, with primary data collection of both qualitative and quantitative data, including a quantitative survey and in-depth qualitative interviews with women who have sought PAC, and policymaker interviews. Zambia's relatively liberal legal context, and the existence of PAC provision facilitates research on issues related to abortion which can have broader lessons for developments elsewhere in the region.The majority of women seeking abortion-related care in Zambia do so for PAC following an unsafe abortion, and have not accessed safe abortion services.This demands better understanding and analysis. Over a 12 month period, all women identified as having undergone either a safe abortion or having received PAC following an attempted induced abortion at a Zambian government health facility were approached for inclusion in the study. We did not interview women identified as having received PAC following a spontaneous abortion. Undoubtedly, some women claiming to have had a spontaneous abortion had in fact attempted to induce an abortion, and at times medical evidence suggested so, however we could not interview them about the attempt as they were not willing to disclose any information on an attempted abortion. As part of the research team we employed two midwives working on the obstetrics and gynaecology ward to act as gatekeepers, identifying suitable women for recruitment and asking them to participate in the study. The research used an innovative mixed methods interview which combined quantitative and qualitative techniques in one interview. Each participant was interviewed by two research assistants (RAs). One RA led the interview, using a conventional interview schedule in the manner of a qualitative semi-structured interview, while the second RA listened and, where possible, completed the quantitative ‘data sheet’. When the first RA has completed the qualitative part of the interview, interviewer two took over and asked the participant any remaining questions not yet answered on the data sheet. This technique allowed us to capture both the individual fine-grained narratives, which are not easily captured in a questionnaire-type survey, especially on such a sensitive area, as well as survey data. Rather than conducting an in-depth qualitative interview and a survey, our method reduced the burden on the respondent, avoiding repetition of questions and reducing the time taken.

Non-Hispanic Black women had the highest rate of infant mortality in the U.S. in 2023. In that year, there were almost ** infant deaths per 1,000 live births among Black women. Leading causes of infant mortality in the U.S. include congenital malformations, disorders related to short gestation and low birth weight, maternal complications, and sudden infant death syndrome.

According to Cognitive Market Research, the global Preeclampsia Diagnostics market size will be USD 2640.0 million in 2025. It will expand at a compound annual growth rate (CAGR) of 10.40% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 976.80 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 765.60 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 633.60 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 100.32 million in 2025 and will grow at a compound annual growth rate (CAGR) of 11.1% from 2025 to 2033.
The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 105.60 million in 2025 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 58.08 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2025 to 2033.
Small Size Vascular Graft category is the fastest growing segment of the Preeclampsia Diagnostics industry

Market Dynamics of Preeclampsia Diagnostics Market

Key Drivers for Preeclampsia Diagnostics Market

Rising Prevalence of Preeclampsia And Related Pregnancy Complications To Boost Market Growth

The increasing number of preeclampsia cases and pregnancy-related complications is a major factor driving the growth of the preeclampsia diagnostics market. Preeclampsia is a serious condition that can lead to high blood pressure and organ damage in pregnant women, posing risks for both mother and baby. As awareness about maternal health improves, more women are seeking early diagnosis and treatment to prevent severe outcomes. Healthcare providers are also emphasizing regular screenings to detect preeclampsia at an early stage. Advancements in diagnostic technology, such as biomarker-based tests and point-of-care devices, further contribute to market expansion. With growing healthcare investments and improved access to medical facilities, the demand for accurate and timely preeclampsia diagnostics continues to rise globally. For instance, in October 2022, according to the Centers for Disease Control and Prevention, Preeclampsia, a pregnancy-specific disorder, is a leading cause of maternal morbidity and is estimated to occur in 5% to 7% of all pregnancies. Globally, preeclampsia is responsible for more than 70,000 maternal deaths and 500,000 fetal deaths annually.

https://blogs.cdc.gov/genomics/2022/10/25/preeclampsia/

Increasing Awareness About Maternal And Fetal Health To Boost Market Growth

Growing awareness about maternal and fetal health is a key factor driving the preeclampsia diagnostics market. More women are prioritizing prenatal care, leading to early detection of pregnancy-related complications like preeclampsia. Governments and healthcare organizations are running awareness campaigns to educate expecting mothers about the importance of regular check-ups. As a result, more pregnant women are undergoing screenings to ensure safe pregnancies. Medical advancements have also made diagnostic tests more accessible and accurate, encouraging early diagnosis and timely intervention. Additionally, doctors and healthcare providers are recommending routine monitoring for high-risk pregnancies. With rising concerns about maternal health and the well-being of newborns, the demand for reliable preeclampsia diagnostic solutions continues to grow across the world.

Restraint Factor for the Preeclampsia Diagnostics Market

High Cost Of Advanced Diagnostic Tests, Will Limit Market Growth

The high cost of advanced diagnostic tests is a major barrier to the growth of the preeclampsia diagnostics market. Many pregnant women, especially in low-income regions, struggle to afford expensive tests, limiting access to early detection and treatment. Due to budget constraints, healthcare facilities may also find it challenging to invest in advanced diagnostic equipment. Insurance coverage for preeclampsia screening varies, making it difficult for some patients to...

Introduction

The Global Preeclampsia Diagnostics Market is projected to grow from USD 2.2 billion in 2024 to approximately USD 5.8 billion by 2034. This reflects a robust compound annual growth rate (CAGR) of 10.2% during the forecast period. Growth is primarily driven by the rising global burden of hypertensive pregnancy disorders, improved diagnostic technologies, and expanded screening programs. Preeclampsia remains a major contributor to maternal and fetal morbidity and mortality, especially in low-resource regions. Early diagnosis can help reduce these complications and support better pregnancy outcomes.

One of the key technological advances fueling this market is biomarker testing. In particular, the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) has gained clinical importance. For example, the Elecsys sFlt-1/PlGF ratio test has shown promising results, with a sensitivity of 91.4% and a specificity of 77.3% at a cutoff of 38. This test is useful for predicting the risk of developing severe preeclampsia within one week among pregnant women hospitalized with hypertension between 23 and 34 weeks of gestation.

Rising global awareness regarding maternal health is another strong growth factor. Preeclampsia accounts for a significant portion of maternal deaths. The Centers for Disease Control and Prevention (CDC) estimates that preeclampsia causes over 70,000 maternal deaths and around 500,000 fetal deaths each year. These figures have led healthcare providers and policymakers to prioritize timely diagnostics and interventions. As awareness increases, more women are undergoing routine antenatal screenings, which is supporting market expansion.

Government organizations are playing a crucial role in strengthening diagnostic access and awareness. The World Health Organization (WHO) has emphasized the need for better preeclampsia diagnostics through its target product profiles and clinical guidance. WHO guidelines recommend routine screening for blood pressure and proteinuria during every antenatal visit. Such protocols are being adopted by national health systems, further integrating diagnostics into standard maternal care.